| Field | Specification |
|---|---|
| Target | |
| Alternative names | Glial fibrillary acidic protein;GFAP;GFAP; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human GFAP, identical to the related rat sequence, and different from the related mouse sequence by two amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets glial fibrillary acidic protein (gene GFAP) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 49.9 kDa, and the supplier reports an observed band at about 50 kDa.
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein expressed mainly in astrocytes. It is the classic marker for astrocytes and for reactive astrogliosis after injury or disease. Mutations in GFAP cause Alexander disease, and GFAP levels are studied as a marker of brain injury.
| Target | Glial fibrillary acidic protein (gene GFAP; UniProt P14136, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg thimerosal; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 49.9 kDa |
| Observed MW | 50 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 0.5–1 µg/mL (Rat, Mouse) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Mouse) |
Samples with a confirmed band (WB): human U251 cells, rat brain tissue, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): rat brain tissue, mouse brain tissue, human brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): mouse brain tissue.
Immunogen
Synthetic peptide from the C-terminal region of human GFAP. The peptide sequence is conserved in rat. It differs from the mouse sequence at two residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places glial fibrillary acidic protein in the cytoplasm. Tissue expression noted by UniProt (human): Expressed in cells lacking fibronectin. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Ranjie Xu et al. (2019) OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome. Cell Stem Cell. 10.1016/j.stem.2019.04.014
Weikang Luo et al. (2025) Surgical-Adjuvant Hydrogel of Full-Natural Bioactive Compounds from Chinese Medicine for Enhanced Traumatic Brain Injury Therapy by Inhibiting Complement Activation. Advanced Functional Materials. 10.1002/adfm.202508893
Liming Li et al. (2022) Stimulation by Exosomes from Hypoxia Preconditioned Human Umbilical Vein Endothelial Cells Facilitates Mesenchymal Stem Cells Angiogenic Function for Spinal Cord Repair. ACS Nano. 10.1021/acsnano.2c02898
Zhao Junli et al. (2022) Activated astrocytes attenuate neocortical seizures in rodent models through driving Na+-K+-ATPase. Nature Communications. 10.1038/s41467-022-34662-2
Li Meiyang et al. (2024) Transcriptional and epigenetic dysregulation impairs generation of proliferative neural stem and progenitor cells during brain aging. Nature Aging. 10.1038/s43587-023-00549-0
Ziming Li et al. (2022) A reactive oxygen species-responsive hydrogel encapsulated with bone marrow derived stem cells promotes repair and regeneration of spinal cord injury. Bioactive Materials. 10.1016/j.bioactmat.2022.04.029
Honghui Wu et al. (2020) Engineering Stem Cell Derived Biomimetic Vesicles for Versatility and Effective Targeted Delivery. Advanced Functional Materials. 10.1002/adfm.202006169
Junkai Zeng et al. (2023) Injectable hydrogel microspheres encapsulating extracellular vesicles derived from melatonin-stimulated NSCs promote neurogenesis and alleviate inflammation in spinal cord injury. Chemical Engineering Journal. 10.1016/j.cej.2023.144121
Jian Cao et al. (2023) ROS filter coating scaffold protects 3D mesenchymal stem cell spheroids for dual-phase treatment of spinal cord injury. Chemical Engineering Journal. 10.1016/j.cej.2023.142192
Jian Cao et al. (2025) An engineering-reinforced extracellular vesicle–integrated hydrogel with an ROS-responsive release pattern mitigates spinal cord injury. Science Advances. 10.1126/sciadv.ads3398
